Michael J. Wick

3.7k total citations
67 papers, 2.4k citations indexed

About

Michael J. Wick is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Michael J. Wick has authored 67 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 22 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Michael J. Wick's work include PI3K/AKT/mTOR signaling in cancer (12 papers), Salivary Gland Tumors Diagnosis and Treatment (9 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Michael J. Wick is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (12 papers), Salivary Gland Tumors Diagnosis and Treatment (9 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Michael J. Wick collaborates with scholars based in United States, Germany and Spain. Michael J. Wick's co-authors include Lily Dong, David Sidransky, Feng Liu, Manuel Hidalgo, Elizabeth Bruckheimer, Fresnida J. Ramos, Amita Patnaik, Ignacio Garrido‐Laguna, N.V. Rajeshkumar and Steven J. Strawn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Michael J. Wick

63 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael J. Wick United States	25	1.2k	915	509	325	246	67	2.4k
Curtis R. Pickering United States	30	1.3k 1.0×	1.0k 1.1×	448 0.9×	655 2.0×	138 0.6×	92	2.6k
Håvard E. Danielsen Norway	32	839 0.7×	810 0.9×	358 0.7×	600 1.8×	338 1.4×	104	3.5k
Matthias Kappler Germany	32	1.5k 1.2×	847 0.9×	171 0.3×	868 2.7×	135 0.5×	122	2.6k
Richard W. Tothill Australia	30	1.7k 1.4×	1.3k 1.4×	467 0.9×	1.4k 4.3×	516 2.1×	63	3.8k
Stephen Yip Canada	30	1.0k 0.8×	565 0.6×	212 0.4×	655 2.0×	261 1.1×	150	2.8k
Lisa M. Sapinoso United States	17	3.4k 2.7×	841 0.9×	250 0.5×	740 2.3×	303 1.2×	19	4.8k
Magali Lacroix‐Triki France	29	1.4k 1.1×	1.3k 1.4×	294 0.6×	1.4k 4.4×	648 2.6×	89	3.1k
Arvind K. Virmani United States	32	3.4k 2.8×	1.4k 1.5×	405 0.8×	1.0k 3.1×	440 1.8×	43	4.8k
Melanie Trivett Australia	13	1.2k 1.0×	1.0k 1.1×	87 0.2×	695 2.1×	290 1.2×	16	2.4k
Adriano Piris United States	27	1.8k 1.4×	2.0k 2.2×	395 0.8×	421 1.3×	441 1.8×	69	3.5k

Countries citing papers authored by Michael J. Wick

Since Specialization

Citations

This map shows the geographic impact of Michael J. Wick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Wick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Wick more than expected).

Fields of papers citing papers by Michael J. Wick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Wick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Wick. The network helps show where Michael J. Wick may publish in the future.

Co-authorship network of co-authors of Michael J. Wick

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Wick. A scholar is included among the top collaborators of Michael J. Wick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Wick. Michael J. Wick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahíllo, Ignacio, et al.. (2023). Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts). Cancers. 15(22). 5402–5402. 1 indexed citations

Lund, J.C., Kyriakos P. Papadopoulos, Thomas Gribbin, et al.. (2023). Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd). Cancer Research. 83(7_Supplement). 3855–3855. 1 indexed citations

Ali, Zaheer, Gabriela Vazquez Rodriguez, Ioannis Vamvakaris, et al.. (2022). Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 41(1). 58–58. 31 indexed citations

Wick, Michael J., et al.. (2022). Upstream Mitigation Is Not All You Need: Testing the Bias Transfer Hypothesis in Pre-Trained Language Models. Proceedings of the 60th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers). 3524–3542. 32 indexed citations

Andersson, Mattias K., Therese Carlsson, Olesya Chayka, et al.. (2020). ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis. 9(1). 5–5. 43 indexed citations

Kinneer, Krista, John Meekin, Arnaud Tiberghien, et al.. (2018). SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clinical Cancer Research. 24(24). 6570–6582. 58 indexed citations

Mandelbaum, Joseph, Ilya Shestopalov, Rachel E. Henderson, et al.. (2018). Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma. The Journal of Experimental Medicine. 215(10). 2673–2685. 53 indexed citations

Yu, Yi, Terence Hall, Sudharshan Eathiraj, et al.. (2017). In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anti-Cancer Drugs. 28(5). 503–513. 21 indexed citations

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

10.

Warner, Kristy A., Felipe Nör, Manoela Domingues Martins, et al.. (2016). Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clinical Cancer Research. 22(14). 3550–3559. 17 indexed citations

11.

Drier, Yotam, Matthew J. Cotton, Kaylyn E. Williamson, et al.. (2016). An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nature Genetics. 48(3). 265–272. 224 indexed citations

12.

Shimizu, Toshio, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2012). The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research. 18(8). 2316–2325. 352 indexed citations

13.

Ivanov, Sergey V., Brandee Brown, Yan Guo, et al.. (2012). TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene. 32(32). 3698–3710. 62 indexed citations

14.

Hidalgo, Manuel, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al.. (2011). A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Molecular Cancer Therapeutics. 10(8). 1311–1316. 303 indexed citations

15.

Wick, Michael J., et al.. (2008). Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: A New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model. Cancer Research. 68(21). 9033–9040. 44 indexed citations

16.

Rodón, Jordi, et al.. (2008). Antitumor effects of sorafenib, bevacizumab and cetuximab as single agents or in combination with an MEK, mTOR or bcl-2 inhibitor, in a SNU-398 human hepatocellular tumor xenograft model.. Cancer Research. 68. 1332–1332. 1 indexed citations

17.

Agur, Zvia, et al.. (2006). Using a Novel Computer Technology for Tailoring Targeted and Chemotherapeutic Drug Schedules to the Individual Patient. Clinical Cancer Research. 12. 1 indexed citations

18.

Dong, Lily, Fresnida J. Ramos, Michael J. Wick, et al.. (2002). Cloning and characterization of a testis and brain-specific isoform of mouse 3′-phosphoinositide-dependent protein kinase-1, mPDK-1β. Biochemical and Biophysical Research Communications. 294(1). 136–144. 10 indexed citations

19.

Wick, Michael J., Lily Dong, Derong Hu, Paul R. Langlais, & Feng Liu. (2001). Insulin Receptor-mediated p62dok Tyrosine Phosphorylation at Residues 362 and 398 Plays Distinct Roles for Binding GTPase-activating Protein and Nck and Is Essential for Inhibiting Insulin-stimulated Activation of Ras and Akt. Journal of Biological Chemistry. 276(46). 42843–42850. 48 indexed citations

20.

Wick, Michael J., Lily Dong, Ramon Riojas, Fresnida J. Ramos, & Feng Liu. (2000). Mechanism of Phosphorylation of Protein Kinase B/Akt by a Constitutively Active 3-Phosphoinositide-dependent Protein Kinase-1. Journal of Biological Chemistry. 275(51). 40400–40406. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact